Men's testosterone prescriptions jump 135% in the UK
Updated
Updated · The Guardian · May 10
Men's testosterone prescriptions jump 135% in the UK
10 articles · Updated · The Guardian · May 10
The rise between 2021 and 2024 has coincided with heavy online advertising by firms including Voy, Hims and Numan, while endocrinologists report more younger men seeking tests and treatment.
Doctors warn low testosterone may be overdiagnosed, with some companies using broad questionnaires, disputed thresholds and sales funnels that can push men toward repeat tests, consultations and long-term testosterone replacement therapy.
Supporters say the NHS misses genuine hypogonadism cases, but specialists stress treatment should follow low blood levels plus symptoms, and note risks including infertility, blood thickening, heart problems at excessive doses and anxiety about masculinity.
When thousands of men report life-changing benefits, should doctors rethink what 'low testosterone' actually means?
After the FDA's 2026 crackdown, can direct-to-consumer health companies survive on wellness marketing alone?